Combantrin 250 mg: Main Uses and Therapeutic Benefits

Targeting Pinworm and Other Susceptible Intestinal Worm Infections

This medication is primarily indicated for addressing common intestinal worm infestations. Its active ingredient is commonly used to help with the treatment of pinworms (threadworms), roundworm, and certain types of hookworm infections. Therapeutic use involves addressing these parasites, which supports the management of the infection and helps manage the spread to others in the household. The medication is considered relevant for the management of these common parasitic conditions.

---

Easing Acute Gastrointestinal Discomfort

Combantrin 250 mg is applied in addressing symptomatic support by helping to alleviate the acute discomfort and irritation caused by the worms. This supports the patient in managing symptoms such as abdominal pain, cramping, general digestive unease, and the intense anal itching often associated with pinworm. The use assists with providing comfort and assists with maintaining functional stability, and is applicable within clinical settings that involve acute or disruptive symptom patterns.

Quick Fact: Relief for Anal Itching (Pruritus Ani)

---

By addressing the underlying parasitic cause, the treatment supports patients during episodes of heightened discomfort, which may help ease the impact of symptoms on routine activities.

Regulatory References

1. DailyMed/NIH FDA Labeling for Pyrantel Pamoate

Who Can and Cannot Use Combantrin 250 mg?

Eligibility for Combantrin 250 mg (Pyrantel Pamoate) is strictly defined by regulatory criteria, establishing who is permitted to use the medication and under which conditions.

Absolute Contraindications

Official regulatory labeling dictates that this medicine must not be used by individuals with a known hypersensitivity or allergy to pyrantel pamoate or any component of the formulation. It is also explicitly contraindicated for patients with a diagnosis of intestinal obstruction.

Age and Established Use

General use is established for adults and children 2 years of age and older. Use is restricted and safety is not established for children less than 2 years old or those weighing under 25 pounds, requiring physician clearance. Furthermore, there is no specific information comparing its use in the geriatric (older adult) population with other age groups.

️ Conditional and Restricted Use

Certain physiological states and comorbidities require medical direction before use. Pregnant individuals and breastfeeding women should not use this product without physician guidance due to a lack of established safety data or a Pregnancy Category C classification. Additionally, individuals with liver disease or significant hepatic impairment must only use the drug after consulting a physician, and caution is noted for patients with coexisting anemia or malnutrition.

The official interaction profile for Combantrin 250 mg (Pyrantel Pamoate) is defined by a low number of officially documented constraints, consistent with the product’s minimal systemic absorption.

Drug–Drug Interaction Restrictions

The most significant interaction restriction documented in regulatory prescribing information involves co-administration with the anthelmintic agent Piperazine. This combination is formally restricted due to the documentation of pharmacodynamic antagonism, an interaction that diminishes the therapeutic effect of both agents. A separate, documented pharmacokinetic interaction involves Theophylline, a xanthine derivative. Co-administration has been officially shown to increase the plasma concentration of Theophylline. These documented interactions establish the primary drug-drug constraints for Pyrantel Pamoate.

Food and Administration Timing

The regulatory labeling explicitly documents the absence of a mandatory timing rule related to administration. The product can be taken at any time of day, with or without meals, milk, or fruit juice, indicating no documented clinically significant interaction with common food or beverages. No specific official restrictions are documented regarding alcohol, herbal products, or other supplements.

Population-Specific Cautionary Notes

A specific cautionary restriction is included in the labeling regarding patients with liver disease (hepatic impairment). This note requires consultation with a physician prior to use, reflecting a condition-dependent constraint relevant to the product’s limited systemic processing and is a mandatory item in the interaction context.

The active pharmaceutical ingredient of Combantrin 250 mg is pyrantel pamoate. Its pharmacodynamic mechanism involves selective accumulation in the nicotinic acetylcholine receptors (nAChRs) situated on the somatic muscle cells of susceptible nematodes. Specifically, pyrantel functions as an agonist at these excitatory nicotinic receptors, structurally mimicking the endogenous neurotransmitter acetylcholine. This molecular interaction triggers persistent and sustained depolarization of the postsynaptic membrane of the parasitic muscle cell.

This continuous depolarization event leads to an uncontrollable, spastic muscle contraction, inducing irreversible neuromuscular blockade. The resulting paralysis of the nematode musculature prevents the organism from maintaining its position within the gastrointestinal lumen. The subsequent lack of muscular tonicity and attachment capability results in the passive expulsion of the paralyzed nematodes by normal intestinal peristalsis, modulating the parasitic load within the host's alimentary canal.

How to Use Combantrin 250 mg

Administration of Pyrantel Pamoate (Combantrin 250 mg) is structured around clinical guidelines, focusing on a precise oral administration protocol and dosage calculation.

---

Dosing and Administration Protocol

Usage Principle	Instruction
Route of Administration	Oral only; not administered by other routes.
Dose Calculation	Based on 11 mg of pyrantel base per kilogram (kg) of body weight, or 5 mg per pound.
Maximum Dose	The calculated dose must not exceed 1 gram (1,000 mg) of pyrantel base in a single administration.
Meal Timing	Administration may occur with or without food; fasting or co-administration of a laxative is not required.

---

Frequency and Special Conditions

Treatment frequency is typically a single oral dose for common infections. For certain cases, such as the management of Enterobius vermicularis (pinworm), the protocol permits a repeat single dose two weeks later if symptoms persist or to manage the parasitic lifecycle. An alternative regimen for specific, more persistent parasitic infections involves administering the weight-based dose once daily for three consecutive days.

Standard guidelines specify that the use is not intended for children under 2 years of age or weighing less than 25 pounds unless directed by a physician. When managing pinworm, a core principle of use is that all members of the household should be treated simultaneously to manage the risk of easy spread.

Research Evidence / Overview of Studies for Combantrin 250 mg

Evidence for Pinworm Infection (Enterobius vermicularis)

Clinical research has studied Pyrantel Pamoate for use against pinworm, a condition involving periods of heightened symptom activity and outcomes related to physical discomfort. The evidence base includes Randomized Controlled Trials (RCTs) and controlled clinical studies that primarily measured the parasitological clearance rate. These studies were conducted in adults and children two years of age and older, with research also examining how to best manage treatment for individuals in the same household.

Findings indicate that the treatment affects the adult worms, resulting in frequently observed measurements of clearance following a single dose. However, the research indicates no observed effect on the egg stage of the parasite. Evidence is limited regarding the long-term outcomes following initial clearance, particularly concerning the frequency of re-infection.

Evidence for Roundworm Infection (Ascaris lumbricoides)

The evidence for roundworm has been extensively evaluated in Systematic Reviews and Meta-analyses that synthesize data from numerous RCTs and field studies. Studies primarily measured two key outcomes: the Parasitological Cure Rate (CR) and the Egg Reduction Rate (ERR). Study populations included school-aged children and adults across various geographic regions.

The studies report frequently reported measurements for both the Cure Rate and Egg Reduction Rate endpoints in the observed populations. Evidence suggests that patients in endemic areas commonly experience re-infection within a few months, and long-term surveillance data on the durability of clearance are not fully established.

Evidence for Hookworm Infections

The evidence base for hookworm infections includes Controlled Clinical Trials and Meta-analyses that evaluated different treatment regimens. Studies primarily monitored Parasitological Cure Rate (CR) and Egg Reduction Rate (ERR). The findings indicate that the single-dose regimen were reported to yield lower measurements for the clearance rate relative to the findings for Roundworm. The evidence describes that multi-day regimens were reported to achieve higher measurements for the parasitological endpoints.

Data show patterns related to decreased reported outcomes that was observed in some studies conducted in areas subject to long-term high-volume use. The research remains uncertain regarding the full extent of knowledge on the most studied regimen length and clearance rates across all hookworm species.

Key Studies & References

1. Anthelmintic effect of oxantel pamoate and pyrantel pamoate
2. Pyrantel Pamoate FDA-Approved Drug Labeling (for general indication and dosing context)

Common questions about Combantrin 250 mg (FAQ)

Q: Is Combantrin 250 mg available over the counter?

A: Yes, official regulatory documents, such as the NIH DailyMed Label in the United States, classify pyrantel pamoate products intended for human use as an Over-The-Counter (OTC) drug. This generally means it is available for purchase without a prescription.

Q: Is Combantrin 250 mg a type of antibiotic?

A: No, pyrantel pamoate is officially classified as an Anthelmintic Agent. This classification indicates that the medicine is used specifically for treating infections caused by parasitic worms, rather than being a type of antibiotic, which targets bacteria.

Q: Why is it sometimes described as a single-dose treatment?

A: Regulatory instructions specify that for certain infections, such as pinworm, the medication is generally taken as a single dose. This protocol is supported by research that indicates the drug can be effective against the adult worms after just one administration.

Q: Why might a person need a second dose of this medicine?

A: The official protocol permits the administration of a repeat single dose, typically two weeks after the first dose. This is sometimes advised to manage the parasitic lifecycle, particularly for pinworm, because the initial dose may not affect the egg stage of the parasite.

Q: Is it commonly used for recurring infections?

A: The official protocol for pinworm infection permits a repeat single dose two weeks after the initial dose if symptoms remain. This acknowledges the potential for re-infection and allows for follow-up treatment under the established guidelines.

Q: Does Combantrin 250 mg work against every type of worm infection?

A: The product is officially indicated and studied for use against specific types of intestinal worms, including pinworm, roundworm, and hookworm. Official product information describes its use against these specific parasites and does not describe it as effective against all known types of parasitic worm infections.

Q: Does Combantrin 250 mg cause drowsiness?

A: Yes, official regulatory documents list drowsiness (somnolence) as one of the documented adverse effects that may occur with the use of pyrantel pamoate. This side effect is classified under Nervous System Disorders.

Q: Why do some people report feeling slightly nauseous after taking it?

A: Nausea is listed in official regulatory documents as one of the commonly reported adverse effects associated with the use of pyrantel pamoate. The exact physiological reasons for why this specific side effect occurs are not typically detailed in general patient information summaries.

Q: Is it normal to see changes in bowel movements after taking this medicine?

A: Changes in bowel movements are commonly expected for two reasons. Official documents list gastrointestinal issues such as diarrhea and abdominal cramps as possible adverse effects. Additionally, the medicine works by paralyzing the worms, which are then expelled from the body via normal bowel movements.

Q: How long does the effect of Combantrin 250 mg last in the body?

A: Official information indicates that the drug is poorly absorbed into the bloodstream. Pyrantel pamoate reaches its highest concentration in the blood within 1 to 3 hours after being taken, and the majority of the dose is naturally expelled through the feces.

Q: Is it true that this medicine can be chewed or crushed?

A: The product is typically presented as an oral tablet, and the official administration protocol defines the route as oral (swallowed). Specific regulatory instructions regarding chewing or crushing the standard oral tablet formulation are generally not detailed in the product's official patient information.

Q: Are there different forms of Combantrin 250 mg besides tablets?

A: Yes, official regulatory documents confirm that in addition to the tablet form, pyrantel pamoate is also produced and regulated as an oral suspension. This suspension is a liquid form of the medicine that may be available in some markets.

Q: What are the general expectations if the symptoms do not improve?

A: Official labeling advises that if symptoms or evidence of the infection are still present after the initial treatment period, consulting a physician is necessary. It is specified that the treatment should not be repeated without medical direction.

Q: What should be done if an overdose is suspected?

A: Regulatory warnings advise that if an overdose of Combantrin 250 mg is suspected, immediate action should be considered. Regulatory warnings advise seeking medical help or contacting a Poison Control Center for guidance.

Q: Is Combantrin 250 mg commonly used in other countries?

A: Yes, the active ingredient, pyrantel, is recognized globally by international health bodies. It is included on the World Health Organization’s Model List of Essential Medicines, indicating its worldwide importance for public health purposes.

Q: Is there a different name for Combantrin 250 mg in different countries?

A: The active ingredient, pyrantel pamoate, is used and regulated worldwide under various international standards. As a result, it is sold under many different local brand names depending on the country or region.

Q: Is a prescription needed for Combantrin 250 mg in all regions?

A: The official regulatory status of pyrantel pamoate is Over-The-Counter (OTC) in many areas. However, the need for a prescription may vary widely depending on the specific country's regulatory classification and local laws regarding drug sales.

Q: Can pets use the same type of medicine, or is it only for humans?

A: Yes, the active ingredient in Combantrin 250 mg (pyrantel pamoate) is also officially regulated for use in various oral dosage forms intended for specific veterinary purposes, such as deworming dogs, puppies, and horses.

The official requirements for the storage and disposal of Combantrin 250 mg (Pyrantel Pamoate) are defined by regulatory authorities to ensure product stability and safety.

Storage and Protection

The product must be stored at a controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). Storage conditions mandate protection from excess heat and moisture. The liquid suspension formulation carries an explicit instruction to DO NOT FREEZE. The medication container must be kept tightly closed, and it must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired product should utilize an authorized drug take-back program. If a take-back program is unavailable, the unused medicine must be removed from its original packaging, mixed with an undesirable substance (such as cat litter or used coffee grounds), sealed in a container, and placed in the household trash, following established FDA guidelines.